U.S. flag

An official website of the United States government

NM_170665.4(ATP2A2):c.2631G>T (p.Glu877Asp) AND Inborn genetic diseases

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Mar 7, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003211440.2

Allele description [Variation Report for NM_170665.4(ATP2A2):c.2631G>T (p.Glu877Asp)]

NM_170665.4(ATP2A2):c.2631G>T (p.Glu877Asp)

Genes:
ATP2A2:ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 [Gene - OMIM - HGNC]
LOC126861638:MED14-independent group 3 enhancer GRCh37_chr12:110782389-110783588 [Gene]
Variant type:
single nucleotide variant
Cytogenetic location:
12q24.11
Genomic location:
Preferred name:
NM_170665.4(ATP2A2):c.2631G>T (p.Glu877Asp)
HGVS:
  • NC_000012.12:g.110345272G>T
  • NG_007097.2:g.68646G>T
  • NG_086136.1:g.789G>T
  • NM_001413013.1:c.2526G>T
  • NM_001413014.1:c.2631G>T
  • NM_001413015.1:c.2256G>T
  • NM_001681.4:c.2631G>T
  • NM_170665.4:c.2631G>TMANE SELECT
  • NP_001399942.1:p.Glu842Asp
  • NP_001399943.1:p.Glu877Asp
  • NP_001399944.1:p.Glu752Asp
  • NP_001672.1:p.Glu877Asp
  • NP_733765.1:p.Glu877Asp
  • NC_000012.11:g.110783077G>T
  • NM_001681.3:c.2631G>T
Protein change:
E752D
Molecular consequence:
  • NM_001413013.1:c.2526G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001413014.1:c.2631G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001413015.1:c.2256G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001681.4:c.2631G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_170665.4:c.2631G>T - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Inborn genetic diseases
Identifiers:
MeSH: D030342; MedGen: C0950123

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV003909596Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Uncertain significance
(Mar 7, 2023)
germlineclinical testing

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From Ambry Genetics, SCV003909596.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

The c.2631G>T (p.E877D) alteration is located in exon 18 (coding exon 18) of the ATP2A2 gene. This alteration results from a G to T substitution at nucleotide position 2631, causing the glutamic acid (E) at amino acid position 877 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: May 1, 2024